OGN

NEUTRALM&A

Organon & Co.

2026-08-11

Price

$13.65

+0.22%

This is the 2026-08-11 snapshot — the signals and analysis for OGN as of this single trading day.

View full OGN research hub →

Score11.0Priority

Signals5/8 DNA0/13 Act · 1/4 Risk

SentimentNEUTRALScore: 7

Volume0.9xvs 20d avg

Analysis

Organon's ultra-low volatility and steady price action are entirely dictated by its pending $14 per share all-cash acquisition by Sun Pharmaceutical. Technical signals like QUIET_STORM and STEADY_CLIMB perfectly align with this merger-arbitrage dynamic, as the stock drifts near the deal price and ignores fundamental noise like its recent Q2 earnings miss. The current RISK_ON macro regime, characterized by exceptionally tight credit spreads (0.78% OAS), provides high conviction that systemic or financing risks will not impede the transaction's expected close in early 2027.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKWEAK FINISH

Key Takeaways

Actionable Thesis: OGN is a pure merger-arbitrage play anchored to the $14 Sun Pharma acquisition price, offering a tight but highly probable spread.
Key Risk: Regulatory blocks, antitrust scrutiny, or shareholder pushback that could delay or break the pending $11.75 billion transaction.
What to Watch: Monitor the $13.49 support level as a strict gauge for market confidence in the deal closing, alongside any regulatory updates.

← Back to 2026-08-11 View Full OGN History →Yahoo Finance &nearr;